208 related articles for article (PubMed ID: 26948662)
1. Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.
Peters M; van der Voort van Zyp JRN; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PSN; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Brachytherapy; 2016; 15(3):296-305. PubMed ID: 26948662
[TBL] [Abstract][Full Text] [Related]
2. Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.
Peters M; van der Voort van Zyp JR; Moerland MA; Hoekstra CJ; van de Pol S; Westendorp H; Maenhout M; Kattevilder R; Verkooijen HM; van Rossum PS; Ahmed HU; Shah TT; Emberton M; van Vulpen M
Radiother Oncol; 2016 Apr; 119(1):104-10. PubMed ID: 26897512
[TBL] [Abstract][Full Text] [Related]
3. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
4.
Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
[TBL] [Abstract][Full Text] [Related]
5. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M; Maenhout M; van der Voort van Zyp JR; Moerland MA; Moman MR; Steuten LM; van Deursen MJ; van Vulpen M
Radiother Oncol; 2014 Jul; 112(1):77-82. PubMed ID: 24998704
[TBL] [Abstract][Full Text] [Related]
6. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
7. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
8. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
9. Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses.
Peters M; Kanthabalan A; Shah TT; McCartan N; Moore CM; Arya M; van der Voort van Zyp JR; Moerland MA; Hindley RG; Emberton M; Ahmed HU
Urol Oncol; 2018 Jan; 36(1):13.e1-13.e10. PubMed ID: 28927782
[TBL] [Abstract][Full Text] [Related]
10. Salvage I seed implantation for prostate cancer with postradiation local recurrence.
Shimbo M; Inoue K; Koike Y; Katano S; Kawashima K
Urol Int; 2013; 90(3):294-300. PubMed ID: 23467122
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
12. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model.
Spiess PE; Levy DA; Mouraviev V; Pisters LL; Jones JS
BJU Int; 2013 Aug; 112(4):E256-61. PubMed ID: 23469778
[TBL] [Abstract][Full Text] [Related]
13. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
14. [Salvage 125I brachytherapy of locally recurrent prostate cancer].
Gesztesi L; Ágoston P; Major T; Gődény M; Andi J; Lengyel Z; Polgár C
Magy Onkol; 2014 Sep; 58(3):219-24. PubMed ID: 25260087
[TBL] [Abstract][Full Text] [Related]
15. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112
[TBL] [Abstract][Full Text] [Related]
16. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.
Mazeron R; Bajard A; Montbarbon X; Gassa F; Malet C; Rocher F; Clippe S; Bringeon G; Desmettre O; Pommier P
Radiat Oncol; 2012 Mar; 7():46. PubMed ID: 22449081
[TBL] [Abstract][Full Text] [Related]
17. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review.
Peters M; Moman MR; van der Poel HG; Vergunst H; de Jong IJ; Vijverberg PL; Battermann JJ; Horenblas S; van Vulpen M
World J Urol; 2013 Apr; 31(2):403-9. PubMed ID: 22903773
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Prostate-specific Antigen (PSA) Nadir and Early Identification of PSA Relapse after 10 Years of Prostate Iodine 125 Seed Brachytherapy in Edinburgh.
McLaren DB; Kerr G; Law AB; Brush JP; Keanie J; Malik J; Keough W; Ronaldson T; Lee J; Kehoe T
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):519-26. PubMed ID: 26093507
[TBL] [Abstract][Full Text] [Related]
19. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure.
Wojcieszek P; Szlag M; Głowacki G; Cholewka A; Gawkowska-Suwińska M; Kellas-Ślęczka S; Białas B; Fijałkowski M
Radiother Oncol; 2016 Jun; 119(3):405-10. PubMed ID: 27165612
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
